Evidence map›Paper›PMID 31422285›Full record

ArticleNeoplasia (New York, N.Y.)2019

SMAR1 favors immunosurveillance of cancer cells by modulating calnexin and MHC I expression.

Aftab Alam, Nandaraj Taye, Sonal Patel, Milind Thube, Jayati Mullick, Vibhuti Kumar Shah, Richa Pant, Tanaya Roychowdhury, Nilanjan Banerjee, Subhrangsu Chatterjee and 5 more

Open access · goldAbstract read
In one paragraph

Article in Neoplasia (New York, N.Y.), 2019. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 13 papers.

0numbers the graph read from it
0cells of the map it votes in
13citing papers in PubMed
0.8field-weighted citation impact, top 29% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

13 citing papers in PubMed, 15 citations in OpenAlex.

  1. Article
  2. Article
  3. Article
  4. Article
  5. Article
  6. Article
  7. The role of cellular proteostasis in antitumor immunity.The Journal of biological chemistry · 2022
    Review
  8. Review
  9. Article
  10. Article
  11. Review
  12. Article
  13. Review
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

15 authors at 5 institutions in 1 country.

Aftab AlamNational Centre for Cell Science, Pune, Maharashtra, India.
Nandaraj TayeNational Centre for Cell Science, Pune, Maharashtra, India.
Sonal PatelNational Centre for Cell Science, Pune, Maharashtra, India.
Milind ThubeICMR-National Institute of Virology, Pune, Maharashtra, India.
Jayati MullickICMR-National Institute of Virology, Pune, Maharashtra, India.
Vibhuti Kumar ShahNational Centre for Cell Science, Pune, Maharashtra, India.
Richa PantNational Centre for Cell Science, Pune, Maharashtra, India.
Tanaya RoychowdhuryIndian Institute of Chemical Biology, Kolkata, India.
Nilanjan BanerjeeBose Institute, Kolkata, India.
Subhrangsu ChatterjeeBose Institute, Kolkata, India.
Rittwika BhattacharyaNetaji Subhas Chandra Bose Cancer Research Institute, Kolkata, India.
Rini RoyNetaji Subhas Chandra Bose Cancer Research Institute, Kolkata, India.
Ashis MukhopadhyayNetaji Subhas Chandra Bose Cancer Research Institute, Kolkata, India.
Devraj MogareNational Centre for Cell Science, Pune, Maharashtra, India.
Samit ChattopadhyayNational Centre for Cell Science, Pune, Maharashtra, India; Indian Institute of Chemical Biology, Kolkata, India. Electronic address: samit@iicb.res.in.
National Centre for Cell Science · INNetaji Subhas Chandra Bose Cancer Research Institute · INBose Institute · INICMR-National Institute of Virology · INIndian Institute of Chemical Biology · IN

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

Down-regulation or loss of MHC class I expression is a major mechanism used by cancer cells to evade immunosurveillance and increase their oncogenic potential. MHC I mediated antigen presentation is a complex regulatory process, controlled by antigen processing machinery (APM) dictating immune response. Transcriptional regulation of the APM that can modulate gene expression profile and their correlation to MHC I mediated antigen presentation in cancer cells remain enigmatic. Here, we reveal that Scaffold/Matrix-Associated Region 1- binding protein (SMAR1), positively regulates MHC I surface expression by down-regulating calnexin, an important component of antigen processing machinery (APM) in cancer cells. SMAR1, a bonafide MAR binding protein acts as a transcriptional repressor of several oncogenes. It is down-regulated in higher grades of cancers either through proteasomal degradation or through loss of heterozygosity (LOH) at the Chr.16q24.3 locus where the human homolog of SMAR1 (BANP) has been mapped. It binds to a short MAR region of the calnexin promoter forming a repressor complex in association with GATA2 and HDAC1. A reverse correlation between SMAR1 and calnexin was thus observed in SMAR1-LOH cells and also in tissues from breast cancer patients. To further extrapolate our findings, influenza A (H1N1) virus infection assay was performed. Upon viral infection, the levels of SMAR1 significantly increased resulting in reduced calnexin expression and increased MHC I presentation. Taken together, our observations establish that increased expression of SMAR1 in cancers can positively regulate MHC I surface expression thereby leading to higher chances of tumor regression and elimination of cancer cells.

Indexed as

Gene Expression Regulation, NeoplasticCalnexinCell Cycle ProteinsCell Line, TumorDNA-Binding ProteinsFlow CytometryGenes, ReporterHistocompatibility Antigens Class IHumansImmunologic SurveillanceInfluenza A virusMolecular Docking SimulationMolecular Dynamics SimulationNuclear ProteinsProteomeProteomicsBANP protein, humanCalnexinCell Cycle ProteinsDNA-Binding ProteinsHistocompatibility Antigens Class INuclear ProteinsProteome

Identifiers

PMID31422285
PMCPMC6706529
OpenAlexW2968834296

What OpenQuestion holds

Textmetadata
LicenceCC BY-NC-ND
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.